Delivery Order SPE2DR25D3016-SPE2DR26FG1FC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,099.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) on September 9, 2025, with completion scheduled for September 10, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,188.80 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on November 14, 2025, with completion scheduled for November 17, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for RINVOQ ER 15 mg tablets (30-count units) valued at $6,223.32 under a firm fixed-price contract with an ultimate completion date of November 5, 2025. This is a non-set-aside, competitively awarded delivery order issued as a child contract against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $11,779.01 on November 18, 2025, for RINVOQ ER 15 mg tablets (30-count packages). This is a firm fixed price, non-set-aside contract with an ultimate completion date of November 19, 2025, and performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,525.88 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $9,780.29 under a firm fixed-price contract type. The award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a delivery order valued at $81,552.22 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 11, 2025, with completion scheduled for September 12, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,492.16 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on November 17, 2025, with an ultimate completion date of November 18, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- SPE2DR25D3016Indefinite Delivery Contract
- SPE2DR25D3016-SPE2DR26FG1FCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,825.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on November 18, 2025, with an ultimate completion date of November 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. The company's SPE2DX prime IDV functions as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. RINVOQ (upadacitinib) is a Janus kinase inhibitor used for treating inflammatory conditions, reflecting AmerisourceBergen's role in supplying specialty medications critical to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.8k | 11/18/25 |